SAN DIEGO, May  04, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ:SMMT). The investigation focuses on Summit&#39;s executive

SMMT

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Investigation Launched into Summit Therapeutics for Potential Securities Violations

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, May  04, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ:SMMT). The investigation focuses on Summit&amp;#39;s executive</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel has initiated an investigation into Summit Therapeutics regarding compliance with federal securities laws, following major declines in stock price after recent disclosures about its HARMONi-3 Phase III trial. Investors may have the opportunity to recover losses if violations are proven, impacting sentiment and future stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel investigates potential securities claims against Summit Therapeutics.</li><li>Investors may recover losses related to Summit&#039;s recent disclosures.</li><li>SMMT stock dropped after revealing interim analysis results.</li><li>Independent Data Monitoring Committee recommended study continuation despite concerns.</li><li>Investigation focuses on compliance with federal securities laws.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Leading a securities investigation which may affect SMMT investor confidence.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This news falls under legal developments, specifically concerning potential securities violations, which can significantly affect stock performance and investor sentiment. Legal scrutiny often leads to increased volatility as the market reacts to uncertain outcomes.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>SMMT&#039;s stock price fell sharply following negative disclosures.</li><li>Ongoing investigation may create further volatility for SMMT shares.</li><li>Potential legal liabilities could impact SMMT&#039;s future cash flow.</li><li>Investor confidence may wane, affecting overall demand for SMMT.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>SMMT stock dropped significantly after April 30 disclosures.</li><li>The HARMONi-3 study&#039;s interim analysis faced scrutiny for high bar of significance.</li><li>Independent Data Monitoring Committee recommended to continue the HARMONi-3 study.</li><li>Johnson Fistel, nationally recognized, is leading the investigation.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investor sentiment and stock price for SMMT may decline in the short term due to ongoing investigation risks.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, May  04, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SMMT">SMMT</a>). The investigation focuses on Summit's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Summit securities?</strong><br></br>If you purchased Summit securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=WTrtokP40790ry_oKPN9U1g7cDsuXcnXBuhl7i40azcHbsA87Px5e80yI58bDrtsbQKEfl9UisGioJ3QTXQ0Uh3Qp2xNTY9LcS-5BKWER8fYoq0AB6gZ8b5_ZZUR3NF6eAW_VxosWvkTUjzR1yU9_F1pLm-XMBuRuL850lax8jZSAy00GQkwnnylCuyQHqTO" rel="nofollow" target="_blank">Click here to join the investigation</a>.</p>  <p>Or for more information, contact Jim Baker at <a href="https://www.globenewswire.com/Tracker?data=9dwokxWGSdh592BhAgE5yvnxU6OP43W_T_SABD3b7syRxtOm-PIGAfPt_GQ_Q0DBp_7CpbzkSNnp_TsNpJCmcz3JbdLnbZdX3UsgGPTWcS8=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On April 30, 2026, Summit reported its first quarter 2026 financial results and provided an update concerning the HARMONi-3 Phase III clinical trial. Among other things, the Company disclosed that, although it had previously announced its intention to perform an interim progression-free survival analysis for the squamous cohort of the HARMONi-3 study, "[t]o achieve statistical significance, there was a meaningfully higher bar than the upcoming planned final PFS analysis based on the minimal alpha spent on the interim analysis." Summit further disclosed that, following review of the early interim PFS analysis by the Independent Data Monitoring Committee, the committee recommended that the study continue as planned.</p>  <p>Following this disclosure, Summit's stock price declined sharply, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Summit complied with the federal securities laws. If you suffered losses from your investment in Summit stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=xYBXYpoTSIPU-aoe40DaImH-3GifPaSeGY9-ejcddVYfWjkgxXUwCz3mhs0QkfO607NRUJDygUagw2WgxSYjSqcggC_xBcWgEgU5bzPOjkA=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="https://www.globenewswire.com/Tracker?data=9dwokxWGSdh592BhAgE5yvnxU6OP43W_T_SABD3b7swlDZSYyro59TiBsEzACj4EXxh6HZeyZITu5K4eAxlbHZaNTJltAtOTCyqU2_1MQlY=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> &#x7C; <a href="https://www.globenewswire.com/Tracker?data=U2o4OManu9On5m3O5iZ-Z4zYTjC4G9zfhNrldw5T-k1izjd-cXXy86cBffnJQgEGp7kRqeGNv8bzdj3gW0ds3v9zorNF_oGhIezWVrlPKhFfxIlsTtB2BzmOHIyMtuqb" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a> </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMjMxNSM3NTc4NzI1IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NzVjNGU4ZGEtNGU1MS00YTBiLWJiNTItZmZiMWI1YmQ2OWJlLTExOTMzNTgtMjAyNi0wNS0wNC1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel has initiated an investigation into Summit Therapeutics regarding compliance with federal securities laws, following major declines in stock price after recent disclosures about its HARMONi-3 Phase III trial. Investors may have the opportunity to recover losses if violations are proven, impacting sentiment and future stock performance.

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News